Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
247 hedge funds and large institutions have $2.28B invested in Apellis Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 108 increasing their positions, 68 reducing their positions, and 49 closing their positions.
346% more call options, than puts
Call options by funds: $56.2M | Put options by funds: $12.6M
59% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 68
2.68% more ownership
Funds ownership: 101.97% → 104.66% (+2.7%)
3% less funds holding
Funds holding: 255 → 247 (-8)
12% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 49
19% less capital invested
Capital invested by funds: $2.8B → $2.28B (-$524M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$49.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$37M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$35.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$27.1M |
| 5 |
Amundi
Paris,
France
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.5M |
| 3 |
Man Group
London,
United Kingdom
|
-$22.5M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$22M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$17.1M |
APLS Hedge Fund Activity: Q2 2025 in Review
247 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2025, worth a combined $2.28B — down 19% from $2.8B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of APLS and 43 opened new positions — a net loss of 6 holders — while 68 trimmed existing stakes and 108 added.
The largest buyer was Marshall Wace, adding an estimated $49.6M. The largest seller was Wellington Management Group, cutting an estimated $61.6M.
- 247 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2025, down from 255 in Q1 2025.
- Funds reported $2.28B of Apellis Pharmaceuticals stock for Q2 2025, down 19% quarter-over-quarter.
- 43 funds opened new Apellis Pharmaceuticals positions in Q2 2025 and 49 closed out, a net change of -6 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2025 was Marshall Wace, an estimated $49.6M added.
- The largest Apellis Pharmaceuticals seller in Q2 2025 was Wellington Management Group, an estimated $61.6M sold.
Based on aggregated 13F filings for Q2 2025.